35 Results for "

self-administration

" in MedChemExpress (MCE) Product Catalog:
Products (35)

35 Results for "self-administration" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-18101A
CAS No.: 206996-13-6
Domaines de recherche:  

Neurological Disease

BD-1063 dihydrochloride is a selective σ-1 receptor antagonist with inhibitory activity against TRPC5 and TRPM3. BD-1063 dihydrochloride exerts anti-hyperalgesic and anti-allodynic effects by inhibiting sustained calcium influx mediated by TRPC5 and TRPM3, and reverses the effects of Carrageenan (HY-125474). BD-1063 dihydrochloride also significantly reduces excessive ethanol self-administration behavior. BD-1063 dihydrochloride is widely used in studies on the mechanisms underlying neuropathic pain, inflammatory hyperalgesia, and alcohol abuse and dependence .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114452
CAS No.: 1307245-86-8
Pureté:  99.91%
Synonyms: BTRX-246040
Target:  

Opioid Receptor

Domaines de recherche:  

Neurological Disease

LY2940094 (BTRX-246040) is a potent, selective and orally available nociceptin receptor (NOP receptor) antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 reduces ethanol self-administration in animal models .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114452A
CAS No.: 1307245-87-9
Synonyms: BTRX-246040 tartrate
Target:  

Opioid Receptor

Domaines de recherche:  

Neurological Disease

LY2940094 (BTRX-246040) tartrate is a potent, brain penetrant, selective and orally available N/OFQ peptide (NOP) receptor antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 tartrate reduces Ethanol self-administration and Ethanol seeking in animal models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-135783
CAS No.: 1314801-63-2
Pureté:  99.94%
Target:  

nAChR

AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a Ki value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121827
CAS No.: 611207-11-5
Pureté:  99.83%
Target:  

Cannabinoid Receptor

Domaines de recherche:  

Metabolic Disease

LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor .
loading...
    loading...
Cat. No.: HY-W002112
CAS No.: 5746-86-1
Synonyms: Nornicotine
(±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .
loading...
    loading...
Cat. No.: HY-135608
CAS No.: 138356-08-8
Pureté:  98.41%
Target:  

Sigma Receptor

Domaines de recherche:  

Neurological Disease

BD-1008 is a nonselective σ receptor antagonist with Kis against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 has an extremely low affinity for the D2 receptor (Ki = 1112 nM) and dopamine transporter (DAT) (Ki > 10,000 nM). BD-1008 significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 blocks the self-administration behavior of σ agonists.BD-1008 can be used for the study of addiction therapy that target the σ receptor .
loading...
    loading...
Cat. No.: HY-111308
CAS No.: 847554-50-1
Domaines de recherche:  

Neurological Disease

RTI-118 is a novel small-molecule neuropeptide S receptor (NPSR) antagonist. RTI-118 can relieve agent addiction including selectively decrease self-administration .
loading...
    loading...
Cat. No.: HY-101478
CAS No.: 57653-26-6
Pureté:  99.60%
Target:  

mGluR Apoptosis

Domaines de recherche:  

Neurological Disease Cancer

Fenobam is a selective and orally active mGluR5 antagonist (IC50=84 nM) that can penetrate the blood-brain barrier. Fenobam shows the Kd values of 54 nM and 31 nM on rat and human recombinant mGlu5 receptors, respectively. Fenobam has anxiolytic activity, inhibits self-administration behavior in mice, and induces apoptosis in cancer cells. Fenobam can be used for research on neurological diseases, cancer and drug addiction .
loading...
    loading...
Cat. No.: HY-147428
CAS No.: 188125-42-0
Pureté:  99.29%
Synonyms: MM-110; (±)​-18-Methoxycoronaridine
Target:  

nAChR Parasite

Domaines de recherche:  

Infection Neurological Disease

Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC50 of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse . Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis .
loading...
    loading...
Cat. No.: HY-12783A
CAS No.: 733717-87-8
Pureté:  ≥98.0%
Target:  

GABA Receptor

Domaines de recherche:  

Neurological Disease

SCH 50911 is a selective, orally active, blood-brain barrier permeable GABA-B receptor (GABA-B Receptor) antagonist with an IC50 of 1.1 μM in rats. SCH 50911 blocks baclofen-induced antitussive effects, regulates neuronal firing and GABA release. SCH 50911 promotes spontaneous seizures during withdrawal in ethanol-dependent rats, alters reward-related neurotransmission, and reduces or suppresses lever responding and self-administration behaviors of alcohol and sucrose in rats. SCH 50911 is applicable to research related to ethanol withdrawal syndrome, absence epilepsy and alcohol use disorder .
loading...
    loading...
Cat. No.: HY-123838
CAS No.: 169675-08-5
Pureté:  99.85%
Target:  

5-HT Receptor

Domaines de recherche:  

Neurological Disease

Ro60-0175 is a potent and selective agonist of 5-HT2C receptor. Ro60-0175 reduces self-administration .
loading...
    loading...
Cat. No.: HY-124597
CAS No.: 1628343-77-0
Pureté:  95.00%
Target:  

Ceramidase

Domaines de recherche:  

Inflammation/Immunology

ARN726 is a potent NAAA (N-acylethanolamine acid amidase) inhibitor with an IC50 of 0.073 µM. ARN726 decreases alcohol self-administration in a dose-dependent manner .
loading...
    loading...
Cat. No.: HY-W002112S
CAS No.: 66148-18-3
Synonyms: Nornicotine-d4
(±)-Nornicotine-d4 is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .
loading...
    loading...
Cat. No.: HY-124110
CAS No.: 1975146-56-5
Target:  

nAChR

Domaines de recherche:  

Neurological Disease

TC299423 is an orally active, brain-penetrant, selective and potent agonist for α6β2 ? and α4β2 ? nicotinic acetylcholine receptors (nAChRs) with anxiolytic and antinociceptive properties. TC299423 acts primarily through α6β2 ? nAChRs that are implicated in the anxiolytic effects of nicotine. TC299423 elicits reward-related behavior mediated through α6β2 ? nAChRs in hypersensitive α6L90’S mice. TC299423 elicits dopamine release and dose not suppress nicotine self-administration in rats. TC299423 is proming for rasearch of addiction and Parkinson’s disease .
loading...
    loading...
Cat. No.: HY-137204
CAS No.: 544450-68-2
Pureté:  99.87%
Target:  

GABA Receptor

Domaines de recherche:  

Neurological Disease

COR659 is a potent and effective GABAB positive allosteric modulator (PAM). COR659 suppresses alcohol and chocolate self-administration in rats .
loading...
    loading...
Cat. No.: HY-138879B
CAS No.: 357425-68-4
Pureté:  99.74%
Synonyms: (1S,5R)-CP-601927
Target:  

nAChR

Domaines de recherche:  

Neurological Disease

CP-601932 ((1S,5R)-CP-601927) is a high-affinity partial agonist at α3β4 nAChR (Ki=21 nM; EC50=~ 3 μM). CP-601932 has the same high-binding affinity at α4β2 nAChR (Ki=21 nM) and an order of magnitude lower affinity for α6 and α7 nAChR subtypes. CP-601932 selectively decreases ethanol but not sucrose consumption and operant self-administration following long-term exposure. CP-601932 can penetrate the CNS .
loading...
    loading...
Cat. No.: HY-107055
CAS No.: 204069-50-1
Target:  

Dopamine Transporter

Domaines de recherche:  

Neurological Disease

RTI 336 is a phenyltropane analog, as well as a potent and selective dopamine transporter (DAT) inhibitor. RTI 336 inhibits addictive agent induced locomotor activity and self-administration in Lewis rats. RTI 336 exhibits inhibitory effects depending on inherent NAc DAT levels .
loading...
    loading...
Cat. No.: HY-100966
CAS No.: 138356-09-9
Pureté:  98.07%
Target:  

Sigma Receptor

Domaines de recherche:  

Neurological Disease

BD-1008 dihydrobromide is a nonselective σ receptor antagonist with Kis against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 dihydrobromide has an extremely low affinity for the D2 receptor (Ki = 1112 nM) and dopamine transporter (DAT) (Ki > 10,000 nM). BD-1008 dihydrobromide significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 dihydrobromide blocks the self-administration behavior of σ agonists.BD-1008 dihydrobromide can be used for the study of addiction therapy that target the σ receptor .
loading...
    loading...
Cat. No.: HY-159624
Target:  

GABA Receptor

Domaines de recherche:  

Neurological Disease

KK-92A, a blood-brain barrier penetrated GABAB positive allosteric modulator (PAM), suppresses alcohol self-administration and cue-induced reinstatement of alcohol seeking in rats .
loading...
    loading...